A Polymorphism in the TC21 Promoter Associates With an Unfavorable Tamoxifen Treatment Outcome in Breast Cancer

Cancer Research - United States
doi 10.1158/0008-5472.can-08-0247
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

TSC22D1 and PSAP Predict Clinical Outcome of Tamoxifen Treatment in Patients With Recurrent Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

Association of Osteopontin Promoter Polymorphism and Aggresivness in Breast Cancer

Sohag Medical Journal
2018English

Impact of UGT2B7 His268Tyr Polymorphism on the Outcome of Adjuvant Epirubicin Treatment in Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2011English

Comprehensive CYP2D6 Genotype and Adherence Affect Outcome in Breast Cancer Patients Treated With Tamoxifen Monotherapy

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

CYP2D6 Genotyping and Tamoxifen in the Treatment of Post-Menopausal Breast Cancer - A Reply

British Journal of Clinical Pharmacology
Pharmacology
2014English

LRG1 mRNA Expression in Breast Cancer Associates With PIK3CA Genotype and With Aromatase Inhibitor Therapy Outcome

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Risk of Endometrial Cancer After Tamoxifen Treatment of Breast Cancer

The Lancet
Medicine
1994English

The C1772T Genetic Polymorphism in Human HIF-1α Gene Associates With Expression of HIF-1α Protein in Breast Cancer

Oncology Reports
MedicineCancer ResearchOncology
1994English

Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation With Worse Outcome in Breast Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy